Drug intelligence / Profile preview

Estima

Development stage: Unknown
Lead developer: Effik
Modality: Small Molecules
Administration: Oral, Vaginal

Overview

Estima is a micronized progesterone medication developed and marketed by the French pharmaceutical company Effik. It is primarily used in gynecology as a component of hormone replacement therapy (HRT) for menopausal women with an intact uterus, where it serves to provide endometrial protection against the effects of estrogen therapy. The drug contains progesterone that is chemically identical to the hormone naturally produced by the human ovary. It acts as a progestogen with anti-estrogenic, weakly anti-androgenic, and anti-aldosterone properties. Estima is available as 100 mg and 200 mg soft capsules and can be administered either orally or vaginally.

Brand names: Estima
Other names: micronized progesteroneprogestérone micronisée

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on Estima.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Estima.

Explore the full profile